Vaccitech, a clinical stage developer of a universal flu vaccine and other vaccine-related products, has received a joint £6m investment from a Korean biotech company, GeneMatrix, and venture capital and private equity firm, Korea Investment Partners.
Vaccitech and GeneMatrix also intend to enter into a formal collaborative agreement that will create business synergies between the companies through expansion of advanced vaccine development programs in Korea. GeneMatrix has recently begun internal vaccine development through a Zika virus vaccine program, backed by a government grant from Korea Centres for Disease Control and Prevention. Vaccitech will use the present investment to advance ongoing clinical projects and expand its research and development efforts.
Tom Evans, Chief Executive Officer at Vaccitech, said:
“The GeneMatrix team is experienced in the infectious disease areas, especially in chronic Hepatitis B and Human Papilloma virus, which are a major unmet medical need, and our vaccine programs in such areas will be quite synergistic.”
Soo-OK Kim, Chief Executive Officer at GeneMatrix, added:
“We hope the combination of Vaccitech’s T-cell induction platform and GeneMatrix’s molecular and therapeutic platform will lead to better clinical development of advanced vaccines and new therapeutics.”
Vaccitech is a spin-out from the University of Oxford and is commercialising decades of viral vector vaccine research conducted at the University’s Jenner Institute. The company’s proprietary T-cell induction platform comprises non-replicating viral vectors that induce some of the most potent cell-mediated immune responses reported in humans against target pathogens and cancer. Vaccitech has multiple vaccine and therapeutic products targeting indications across infectious diseases and oncology.
Vaccitech uses clinically validated non-replicating viral vectors for the prophylaxis and treatment of conditions in which the induction of T-cells, along with antibodies, are critical for prevention or control. Vaccitech (www.vaccitech.co.uk) is a clinical stage vaccine company originating from the University of Oxford’s Jenner Institute, one of the oldest and most renowned vaccine research centres in the world. The founders of the company are Professor Adrian Hill (Director of the Jenner Institute) and Professor Sarah Gilbert (Lead in influenza and MERS), who combine their exceptional scientific skills with regulatory and manufacturing experience. The management team has decades of experience in the development of vaccine and therapeutic products.
GeneMatrix (www.genematrix.net) is a KOSDAQ listed company, founded in 2000, that uses clinical data to improve human health and welfare. For almost two decades the company has developed theranostic solutions for health problems to become the Korean market leader for HBV, HCV, HIV, and more recently, Human Papilloma Virus genotyping. GeneMatrix has long term plans to devise optimal personalised treatment solutions incorporating its proprietary molecular diagnostics platforms and immunotherapeutic approach.
About Korea Investment Partners
Korea Investment Partners (kipvc.com) is a leading venture capital & private equity firm that has over 30 years of experience in providing venture capital to bold and innovative entrepreneurs who want to change the world. Korea Investment Partners invests in leading pioneers like Kakao (KOSDAQ:035720), Naver (KRX:035420), YG Entertainment (KOSDAQ:122870), Bodyfriend, Osstem Implant (KOSDAQ:048260), Doubleu Games (KOSDAQ:192080) and Didi Chuxing. KIP manages over 20 venture and private equity funds with over US $2 billion in total assets under management. The company operates globally from its Seoul headquarters office with other locations in Shanghai, Beijing, and Sunnyvale.